CD8A and cancer: Moreover, CD8+CTLs, due to their potent anticancer action, form the backbone of currently available cancer immunotherapies, such as immune-checkpoint inhibitors (ICIs) and chimeric-antigen receptor (CAR) T cell therapies [109,158,159].